Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2086387 | 0.82 | TSHR (0.42) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL6539479 | 0.79 | KCNH2 (0.39) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL841129 | 0.77 | — | — | |
| SCHEMBL6539704 | 0.77 | KCNH2 (0.39) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL9769982 | 0.76 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL3031013 | 0.76 | ALDH1A1 (0.39) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL1994023 | 0.75 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL1262872 | 0.75 | FDPS (0.36) | ALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL10042012 | 0.75 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTHPGDRAB9A | |
| SCHEMBL23108665 | 0.73 | KMT2A (0.42) | ALDH1A1LMNAMAPTHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555602-B | Heterocyclic compounds as STING modulators | 百济神州有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-114555602-A | Heterocyclic compounds as STING modulators | 百济神州有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2021068866-A1 | HETEROCYCLIC COMPOUNDS AS STING MODULATORS | BEIGENE, LTD. (KY) | 2021-04-15 | — | — | WO | claimed |
| WO-2007114672-A1 | AGENT FOR THE PREVENTION AND TREATMENT OF METABOLIC BONE DISEASE BY ENHANCING OSTEOPROTEGERIN SECRETION | OSCOTEC INC. (KR) | 2007-10-11 | — | — | WO | claimed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | claimed |
| CN-114555602-B | Heterocyclic compounds as STING modulators | 百济神州有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3694856-B1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-114555602-A | Heterocyclic compounds as STING modulators | 百济神州有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021068866-A1 | HETEROCYCLIC COMPOUNDS AS STING MODULATORS | BEIGENE, LTD. (KY) | 2021-04-15 | — | — | WO | disclosed |
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| EP-3694856-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-08-19 | — | — | EP | disclosed |
| CN-105732637-B | Heteroaromatic compounds and their use in medicine | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-0724197-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-07-31 | — | — | EP | disclosed |
| EP-0710887-A1 | Photopolymerizable composition | FUJI PHOTO FILM CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-4139625-A | 5-(Substituted triphenylmethyl)picolinamides and their use as anti-acne agents | SCHERING CORPORATION (US) | 1979-02-13 | — | — | US | disclosed |
| US-4138488-A | Diphenylmethyl picolinic acid derivatives and their use as anti-acne agents | SCHERING CORPORATION (US) | 1979-02-06 | — | — | US | disclosed |
| US-4133887-A | Trityl picolinic acid derivatives and their use as anti-acne agents | SCHERING CORPORATION (US) | 1979-01-09 | — | — | US | disclosed |
| US-4127662-A | ANTIACNE | SCHERING CORPORATION (US) | 1978-11-28 | — | — | US | disclosed |
| US-4123433-A | ANTIACNE AGENTS | SCHERING CORPORATION (US) | 1978-10-31 | — | — | US | disclosed |
| US-4044140-A | Trityl picolinic acid derivatives and their use as anti-acne agents | SCHERING CORPORATION (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SLC10A1, CYP11B2, CYP11B1 | ALDH1A1 1478/4885LMNA 1274/4885MAPT 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.